ArticlesDifferential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
Introduction
Postmenopausal women are often prescribed oestrogen-replacement therapy (ERT) to treat menopausal symptoms and to prevent osteoporosis. Harmful effects of ERT include breast cancer1 and VTE. ERT might also increase the risk of coronary heart disease and stroke.1
Despite evidence that oral oestrogen activates blood coagulation in postmenopausal women2 and might be thrombogenic,3 ERT has long been believed to have little effect on the risk of VTE.4 Early studies of VTE risk in ERT users provided inconclusive results.4 However, results of recent observational studies showed consistent associations between current use of ERT and increased risk of VTE in postmenopausal women.5, 6, 7, 8, 9, 10 These findings have been confirmed by randomised clinical trials.11
Most previous studies of VTE risk in ERT users were done in women using oral oestrogen.12 Transdermal oestrogen is widely used in European countries, especially in France, and has little or no effect on haemostasis.13 Clinical data assessing the effect of transdermal ERT on thrombotic processes are scarce. Therefore, we did a case-control study to investigate the effect of the route of oestrogen administration on VTE risk.
Section snippets
Selection and ascertainment of cases and controls
During 1999–2002, we recruited 155 consecutive cases with a first documented episode of idiopathic VTE at seven teaching hospitals in France. Eligible cases were postmenopausal women aged 45–70 years and living in the vicinity of the recruiting hospitals. Women were excluded if they reported a previous episode of VTE; had a contraindication for ERT (history of breast cancer, VTE, valvular cardiopathy, coronary heart disease, or stroke); or had a predisposing factor for VTE (history within the
Results
Table 1 shows the characteristics of the study population. Mean body-mass index was higher in cases than in controls. Cases were more likely than controls to have reported family history of VTE and history of varicose veins. 24 diabetic controls were matched to cases with either hypertension or obesity and, therefore, a higher proportion of controls than cases reported diabetes. However, the proportion of women at high risk was similar among cases and controls (28% and 26%, respectively).
Discussion
Our data show an increased risk of VTE in current users of oral ERT compared with non-users. Current users of oral ERT seem to be at higher risk of VTE than users of transdermal ERT. There was no association between VTE risk and use of transdermal ERT.
Our results for current users of oral ERT are consistent with previous data. Observational studies reported a greatly increased risk of VTE in current users of oral ERT.4 This finding is in accord with those in recent randomised trials,11 and
References (24)
- et al.
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
Lancet
(1996) - et al.
Risk of venous thromboembolism in users of hormone replacement therapy
Lancet
(1996) - et al.
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Lancet
(1996) - et al.
Evidence from randomised trials on the long-term effects of hormone replacement therapy
Lancet
(2002) - et al.
Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 β-estradiol: comparison with conventional oral estrogens used for hormone replacement
Am J Obstet Gynecol
(1985) - et al.
Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study
Atherosclerosis
(2003) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial
JAMA
(2002)- et al.
Coagulation activation following estrogen administration in postmenopausal women
Thromb Haemost
(1992) Initial findings leading to modifications of its research protocol
JAMA
(1970)- et al.
Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force
Ann Intern Med
(2002)